The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 14

PMID 39272894

Authors

Haruka Kuno

Naoya Nishioka

Tadaaki Yamada

Yusuke Kunimatsu

Akihiro Yoshimura

Soichi Hirai

Shun Futamura

Taiki Masui

Masashi Egami

Yusuke Chihara

Koichi Takayama

Affiliations

Soon will be listed here.

Abstract

Sarcopenia assessed at a single time point is associated with the efficacy of immunotherapy, and we hypothesized that longitudinal changes in muscle mass may also be important. This retrospective study included patients with non-small cell lung cancer (NSCLC) who received durvalumab treatment after concurrent chemoradiotherapy (CCRT) between January 2017 and April 2023. Muscle loss and sarcopenia were assessed based on the lumbar skeletal muscle area. Patients with a decrease in muscle area of 10% or more during CCRT were categorized into the muscle loss group, while those with a decrease of less than 10% were categorized into the muscle maintenance group. We evaluated the relationship between muscle changes during CCRT and the efficacy of durvalumab treatment. Among the 98 patients, the muscle maintenance group had a significantly longer PFS of durvalumab treatment compared to the muscle loss group (29.2 months [95% confidence interval (CI): 17.2-not reached] versus 11.3 months [95% CI: 7.6-22.3]; = 0.008). The multivariable analysis confirmed that muscle change was a significant predictor of a superior PFS (HR: 0.47 [95% CI: 0.25-0.90]; the -value was less than 0.05). In contrast, the OS between the groups did not differ significantly (not reached [95% CI: 21.8 months-not reached] and 36.6 months [95% CI: 26.9-not reached]; = 0.49). Longitudinal muscle changes during CCRT are a predictor of durvalumab's efficacy in patients with NSCLC after CCRT.

References

Rounis K, Makrakis D, Tsigkas A, Georgiou A, Galanakis N, Papadaki C . Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Transl Lung Cancer Res. 2021; 10(8):3538-3549. PMC: 8435387. DOI: 10.21037/tlcr-21-460. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

Loosen S, Van den Bosch V, Gorgulho J, Schulze-Hagen M, Kandler J, Jordens M . Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy. J Clin Med. 2021; 10(7). PMC: 8036296. DOI: 10.3390/jcm10071361. View

Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C . Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report. Thorac Cancer. 2019; 10(2):347-351. PMC: 6360197. DOI: 10.1111/1759-7714.12965. View

Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N . Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. J Clin Med. 2019; 8(4). PMC: 6518257. DOI: 10.3390/jcm8040450. View

Minami S, Ihara S, Tanaka T, Komuta K . Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer. World J Oncol. 2020; 11(1):9-22. PMC: 7011908. DOI: 10.14740/wjon1225. View

10.

Myers J . Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum. 2008; 35(5):802-7. DOI: 10.1188/08.ONF.802-807. View

11.

Almand B, Clark J, Nikitina E, Van Beynen J, English N, Knight S . Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2000; 166(1):678-89. DOI: 10.4049/jimmunol.166.1.678. View

12.

Ballaro R, Beltra M, De Lucia S, Pin F, Ranjbar K, Hulmi J . Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 2019; 33(4):5482-5494. DOI: 10.1096/fj.201801862R. View

13.

Ricciuti B, Wang X, Alessi J, Rizvi H, Mahadevan N, Li Y . Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022; 8(8):1160-1168. PMC: 9204620. DOI: 10.1001/jamaoncol.2022.1981. View

14.

Blauwhoff-Buskermolen S, Versteeg K, de van der Schueren M, den Braver N, Berkhof J, Langius J . Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(12):1339-44. DOI: 10.1200/JCO.2015.63.6043. View

15.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

16.

Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures J, Pujol J . Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020; 143:19-26. DOI: 10.1016/j.lungcan.2020.03.003. View

17.

Baracos V, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S . Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010; 91(4):1133S-1137S. DOI: 10.3945/ajcn.2010.28608C. View

18.

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View

19.

Wang D, DuBois R . Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015; 36(10):1085-93. PMC: 5006153. DOI: 10.1093/carcin/bgv123. View

20.

Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L . Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12):1301-1311. PMC: 9015199. DOI: 10.1200/JCO.21.01308. View